Aurora and Ethypharm Reaffirm their Commitment to Promote Access to Medical Cannabis for French Patients
Portfolio Pulse from Benzinga Newsdesk
Aurora Europe GmbH, a subsidiary of Aurora Cannabis Inc. (NASDAQ:ACB), and Ethypharm have been selected by the French General Directorate of Health as exclusive suppliers of dried medical cannabis flower until the end of the French trial period, which has been extended until March 2024.
May 30, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aurora Cannabis (NASDAQ:ACB) has been selected as an exclusive supplier of medical cannabis for the French trial period, which has been extended until March 2024.
Aurora Cannabis being selected as an exclusive supplier for the French trial period is a positive development for the company. The extension of the trial period until March 2024 provides a longer timeframe for potential revenue generation and market penetration in France. This news is highly relevant to ACB and important for investors as it signifies a potential growth opportunity for the company.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100